Arca
Skip to content
Tools
Tools

NDA 208419: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 208419's history or Actavis's company page.

On Sep 26, 2017, FDA declined to approve NDA 208419 (NDA 208419) from Actavis, L.L.C. in its present form, citing facility inspections, microbiology. The application was later approved.

  • Letter date: Sep 26, 2017
  • Application: NDA 208419
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspectionsMicrobiology

The Letter

Text from openFDA

During recent inspection of Sindan-Pharma S.R.L (FEI: 3005566806) manufacturing facility for this application, our field investigators conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before...โ€ฆ openFDA did not return the full text just now. Open it in the letter search.

Other Letters on This Application

  • PemetrexedJun 26, 2018 ยท NDA 208419 ยท later approved

Record

Company
Actavis, L.L.C.
Application
NDA 208419
Status in openFDA
Approved
Review division
Office of Hematology and Oncology Products

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.